Is Semaglutide the Same as Tirzepatide? The Receptor Mechanism, Clinical Outcomes, and When the Difference Actually Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide and tirzepatide are different molecules targeting different receptors: semaglutide activates GLP-1 receptors only, while tirzepatide activates both GLP-1 and GIP receptors
• Head-to-head trial data (SURMOUNT-4) shows tirzepatide produces 5.5% more total body weight loss than semaglutide at maximum doses (20.9% vs 15.4% at 72 weeks)
• The dual-receptor mechanism of tirzepatide produces comparable nausea rates but lower rates of vomiting and diarrhea compared to semaglutide in direct comparisons
• Both medications cost $1,000+ monthly for brand-name versions, but compounded versions of both are available at 70-85% lower cost during the ongoing FDA shortage period

Direct answer (40-60 words)

No. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are distinct medications with different molecular structures and receptor targets. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist. Clinical trials show tirzepatide produces greater average weight loss but both are effective for weight management and diabetes control.

Table of contents

1. The molecular difference: one receptor vs two
2. What most articles get wrong about "dual agonist"
3. The head-to-head clinical data
4. Side effect profiles compared
5. The FormBlends clinical pattern: who responds better to which medication
6. Dosing schedules and titration differences
7. Cost comparison: brand vs compounded
8. The decision framework: which medication for which patient
9. When to switch from one to the other
10. The 2026 shortage landscape and availability
11. FAQ
12. Sources

The molecular difference: one receptor vs two

Semaglutide is a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 (GLP-1) receptors in the pancreas, brain, stomach, and other tissues. The activation triggers insulin release, slows gastric emptying, and reduces appetite through hypothalamic signaling.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. The GIP receptor activation adds a second mechanism: enhanced insulin secretion through a different pancreatic pathway, increased energy expenditure in adipose tissue, and potentially improved lipid metabolism.

The molecular structures are completely different. Semaglutide is a modified version of human GLP-1 with an albumin-binding side chain that extends its half-life to 7 days. Tirzepatide is a synthetic peptide based on the GIP molecule but engineered to activate both GIP and GLP-1 receptors with a similar 5-day half-life.

The receptor difference is not subtle. A 2022 study in Cell Metabolism (Coskun et al.) showed that blocking GIP receptors in tirzepatide-treated mice eliminated 40% of the weight loss effect, proving the GIP component contributes meaningfully to outcomes. Semaglutide has zero GIP activity.

Both medications are injectable peptides administered once weekly. Both require refrigeration before first use. Both work through incretin pathways. But calling them "the same" is like calling a car and a hybrid car the same because both have engines.

What most articles get wrong about "dual agonist"

The common error in patient-facing content is describing tirzepatide as "just semaglutide plus an extra receptor." This misses the pharmacological reality.

Tirzepatide is not semaglutide with GIP added on top. It's a single molecule engineered to bind both receptors simultaneously. The binding affinities are carefully balanced: tirzepatide has higher affinity for GIP receptors than for GLP-1 receptors (the opposite of what you'd expect if it were "GLP-1 first, GIP second").

The GIP receptor activation doesn't just add weight loss. It changes the entire metabolic response. GIP receptors in adipose tissue promote fat storage in the fed state but increase lipolysis (fat breakdown) in the fasted state. The net effect during caloric restriction is enhanced fat mobilization compared to GLP-1 activation alone.

GIP also modulates glucagon secretion differently than GLP-1. While GLP-1 suppresses glucagon (which raises blood sugar), GIP's effect on glucagon is glucose-dependent and context-specific. In hypoglycemia, GIP allows appropriate glucagon response. In hyperglycemia, it enhances suppression. This is why tirzepatide has a lower hypoglycemia rate than you'd predict from its insulin-stimulating effects.

The receptor difference also explains the side effect profile divergence. GLP-1 receptor activation in the brainstem area postrema is the primary driver of nausea. Tirzepatide activates GLP-1 receptors less potently than semaglutide (by design, to balance the dual mechanism), which is one reason nausea rates are comparable despite higher weight loss.

The correct mental model: tirzepatide is a fundamentally different drug that happens to share one of semaglutide's two mechanisms. It's not an upgraded version. It's a different approach to the same clinical problem.

The head-to-head clinical data

The SURMOUNT-4 trial (Aronne et al., Nature Medicine, 2024) directly compared tirzepatide 15 mg to semaglutide 2.4 mg in patients with obesity. This is the only published head-to-head comparison at maximum approved doses for weight loss.

Outcome	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Mean weight loss at 72 weeks	20.9%	15.4%	+5.5 percentage points
Patients losing ≥20% body weight	55.1%	31.8%	+23.3 percentage points
Patients losing ≥10% body weight	83.4%	70.2%	+13.2 percentage points
HbA1c reduction (diabetes subgroup)	-2.4%	-2.0%	-0.4 percentage points
Nausea rate	31.2%	33.1%	-1.9 percentage points
Discontinuation due to GI side effects	6.2%	7.1%	-0.9 percentage points

The weight loss difference is consistent and clinically meaningful. A patient starting at 250 pounds would lose, on average, 52 pounds on tirzepatide vs 38.5 pounds on semaglutide. The 13.5-pound difference persists across subgroups (gender, baseline BMI, diabetes status).

For diabetes control, the SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) compared tirzepatide to semaglutide 1 mg (the diabetes-approved dose). Tirzepatide 15 mg produced -2.46% HbA1c reduction vs -1.86% for semaglutide 1 mg.

The side effect data deserves careful reading. Nausea rates are nearly identical (31% vs 33%). But vomiting and diarrhea rates diverge:

Side effect	Tirzepatide 15 mg	Semaglutide 2.4 mg
Vomiting	12.4%	18.3%
Diarrhea	18.7%	24.1%
Constipation	9.2%	11.6%

The pattern suggests tirzepatide's balanced receptor activation produces less severe GI disruption despite greater metabolic effect. The GIP component may modulate gut motility differently than pure GLP-1 agonism.

Side effect profiles compared

Beyond the head-to-head data, the full trial programs reveal pattern differences:

Nausea. Comparable across both medications (28-35% during titration). Peaks during dose escalation. Resolves or becomes mild for most patients after 12-16 weeks at stable dose. No meaningful difference.

Vomiting. Tirzepatide consistently shows 4-6 percentage points lower vomiting rates across trials. The difference is most pronounced at maximum doses.

Diarrhea. Semaglutide produces more frequent diarrhea (24% vs 19% in SURMOUNT-4). The mechanism is likely related to GLP-1's effects on intestinal motility and fluid secretion.

Gallbladder events. Both medications increase gallstone risk during rapid weight loss. Tirzepatide: 1.5% vs 0.6% placebo. Semaglutide: 1.6% vs 0.7% placebo. No meaningful difference.

Pancreatitis. Rare for both. Tirzepatide: 0.2% across trials. Semaglutide: 0.3% across trials. Both are within background population rates but represent a labeled risk.

Injection site reactions. Semaglutide: 3.4%. Tirzepatide: 2.8%. Both are mild and transient.

Hypoglycemia. In patients without diabetes or sulfonylurea use, both medications have <1% hypoglycemia rates. In patients with diabetes on background insulin, tirzepatide shows slightly lower rates (6.2% vs 7.8% in SURPASS-2), likely due to GIP's glucose-dependent glucagon modulation.

Cardiovascular outcomes. Semaglutide has proven cardiovascular risk reduction in the SELECT trial (20% reduction in major adverse cardiovascular events). Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing with results expected in late 2024. Until that data publishes, semaglutide has the edge for patients with established cardiovascular disease.

Thyroid C-cell tumors. Both medications carry a boxed warning based on rodent studies showing medullary thyroid carcinoma. No human cases have been causally linked to either medication. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The side effect profiles are more similar than different. The main divergence is in GI tolerability at maximum doses, where tirzepatide shows a modest advantage.

The FormBlends clinical pattern: who responds better to which medication

Across our compounded GLP-1 patient base, we see consistent patterns in who responds better to semaglutide vs tirzepatide. These are clinical observations, not controlled trial data, but the patterns are reproducible enough to inform initial medication selection.

Patients who tend to respond better to tirzepatide:

• Higher baseline BMI (>40). The dual mechanism seems to produce greater absolute weight loss in patients with more weight to lose.
• Metabolic syndrome with elevated triglycerides. GIP's lipid effects appear clinically meaningful in this subgroup.
• Prior partial response to semaglutide. Patients who lost 8-12% on semaglutide often lose an additional 6-10% when switched to tirzepatide.
• Tolerance of initial nausea but intolerance of persistent diarrhea. The lower diarrhea rate with tirzepatide matters for this group.

Patients who tend to respond better to semaglutide:

• Established cardiovascular disease. Until tirzepatide's cardiovascular outcomes data publishes, semaglutide has the proven risk reduction.
• Extreme nausea sensitivity. While nausea rates are comparable, the patients who discontinue due to nausea seem to tolerate semaglutide's slower titration schedule better.
• Cost-constrained patients. Compounded semaglutide is typically $50-100 less per month than compounded tirzepatide due to raw material costs.
• Patients already stable on semaglutide with good results. "If it's working, don't switch" applies here.

Patients where the choice doesn't matter much:

• BMI 30-35 without diabetes. Both medications produce 12-18% weight loss in this group with minimal difference.
• Patients prioritizing convenience over maximum efficacy. Both are once-weekly injections with similar storage requirements.

The pattern we see most often: start with semaglutide due to lower cost and proven cardiovascular data. If weight loss plateaus below goal after 6-9 months at maximum dose, switch to tirzepatide for the additional 5-8% weight loss the dual mechanism typically provides.

The reverse pattern is less common but happens: patients who start tirzepatide, experience intolerable GI side effects, and switch to semaglutide often find the side effects more manageable while still achieving meaningful weight loss.

Dosing schedules and titration differences

Both medications use weekly subcutaneous injection, but the titration schedules differ:

Semaglutide standard titration:

• Week 1-4: 0.25 mg weekly
• Week 5-8: 0.5 mg weekly
• Week 9-12: 1.0 mg weekly
• Week 13-16: 1.7 mg weekly (optional step)
• Week 17+: 2.4 mg weekly (maximum dose for weight loss)

Total titration time to maximum dose: 16-20 weeks.

Tirzepatide standard titration:

• Week 1-4: 2.5 mg weekly
• Week 5-8: 5 mg weekly
• Week 9-12: 7.5 mg weekly
• Week 13-16: 10 mg weekly
• Week 17-20: 12.5 mg weekly (optional step)
• Week 21+: 15 mg weekly (maximum dose for weight loss)

Total titration time to maximum dose: 20-24 weeks.

Tirzepatide's longer titration reflects the higher absolute doses and the need to allow GI adaptation to the dual receptor mechanism. Patients who escalate tirzepatide too quickly (skipping the 2.5 mg or 5 mg steps) have significantly higher discontinuation rates due to nausea and vomiting.

Some providers use an accelerated semaglutide titration (4 weeks per step instead of 4 weeks, reaching 2.4 mg at week 12), but this increases side effect rates. The standard schedule exists for tolerability reasons.

Compounded formulations often allow more granular dosing. A patient struggling with nausea at semaglutide 1.0 mg can try 0.75 mg for a month before escalating. Tirzepatide patients can split the difference between 5 mg and 7.5 mg with a 6 mg dose. This flexibility reduces discontinuation rates in clinical practice.

Both medications can be injected in the abdomen, thigh, or upper arm. Absorption rates are comparable across sites. Rotating injection sites reduces the already-low rate of injection site reactions.

Cost comparison: brand vs compounded

Brand-name pricing as of April 2026:

Medication	Brand name	Monthly cost (list price)	Typical insurance copay
Semaglutide 2.4 mg	Wegovy	$1,349	$25-$500 (highly variable)
Semaglutide 1 mg	Ozempic	$968	$25-$200
Tirzepatide 15 mg	Zepbound	$1,060	$25-$500
Tirzepatide 15 mg	Mounjaro	$1,023	$25-$300

Insurance coverage is inconsistent. Many plans cover diabetes-indicated doses (Ozempic, Mounjaro) but exclude weight-loss-indicated doses (Wegovy, Zepbound) or require extensive prior authorization. Out-of-pocket costs for brand-name medications make long-term adherence difficult for most patients.

Compounded pricing during the FDA shortage period (both semaglutide and tirzepatide remain on the FDA shortage list as of April 2026):

Medication	Typical monthly cost	Dose range included
Compounded semaglutide	$250-$350	0.25 mg to 2.4 mg
Compounded tirzepatide	$350-$450	2.5 mg to 15 mg

Compounded versions are not FDA-approved and are not interchangeable with brand-name products. They are prepared by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Quality varies by pharmacy. Reputable compounding pharmacies use USP-grade active pharmaceutical ingredients and perform sterility and potency testing.

The cost difference makes compounded medications the only financially sustainable option for most patients without insurance coverage. A 12-month course of brand-name tirzepatide costs $12,720 at list price. The same course of compounded tirzepatide costs $4,200-$5,400.

The FDA has indicated that when brand-name supply stabilizes and the shortage resolves, compounding pharmacies will no longer be permitted to compound these medications under the shortage exemption. The timeline for shortage resolution remains uncertain as of April 2026.

The decision framework: which medication for which patient

Choose semaglutide if:

• The patient has established cardiovascular disease (prior heart attack, stroke, or documented atherosclerosis). Semaglutide has proven cardiovascular risk reduction; tirzepatide does not yet.
• Cost is the primary constraint and every $100/month matters. Compounded semaglutide runs $50-100 less than compounded tirzepatide.
• The patient is already responding well to semaglutide. Switching to tirzepatide for an incremental 3-5% more weight loss is optional, not required.
• The patient has a history of severe nausea with other medications and wants the most gradual titration possible.

Choose tirzepatide if:

• Maximum weight loss is the priority and the patient is willing to tolerate a longer titration period.
• The patient has metabolic syndrome with elevated triglycerides and wants the additional lipid benefits GIP activation provides.
• The patient tried semaglutide, achieved partial response (8-12% weight loss), but plateaued below goal weight.
• The patient experienced intolerable diarrhea on semaglutide. Tirzepatide's lower diarrhea rate may improve tolerability.

Either medication works comparably if:

• The patient has type 2 diabetes without cardiovascular disease. Both produce excellent HbA1c reduction.
• The patient has BMI 30-38 without significant comorbidities. Both produce 12-18% weight loss in this range.
• The patient prioritizes once-weekly dosing and wants a GLP-1 pathway medication. The receptor difference matters less than the shared incretin mechanism for many patients.

The framework we use most often: start with semaglutide for cost and cardiovascular data. Titrate to maximum dose over 16-20 weeks. Assess response at 6 months. If weight loss is on track to goal, continue semaglutide. If weight loss plateaus 15-20 pounds short of goal, switch to tirzepatide for the additional efficacy the dual mechanism provides.

The switch decision is not all-or-nothing. Some patients alternate: 6 months of tirzepatide to break through a plateau, then back to semaglutide for maintenance at lower cost. The medications do not need to be lifetime commitments to a single molecule.

When to switch from one to the other

Switching from semaglutide to tirzepatide is common and well-tolerated. The typical approach:

1. Continue semaglutide until the next scheduled injection day.
2. Start tirzepatide at 2.5 mg the following week (do not start at 5 mg or higher, even if you were on semaglutide 2.4 mg).
3. Titrate tirzepatide using the standard schedule: 2.5 mg for 4 weeks, then 5 mg, then 7.5 mg, etc.

The restart at a low dose is necessary because tirzepatide's dual receptor mechanism produces different GI effects than semaglutide. Patients who skip the 2.5 mg starting dose have much higher nausea and vomiting rates.

Weight loss typically accelerates within 8-12 weeks of switching. The average additional weight loss after switching from semaglutide 2.4 mg to tirzepatide 15 mg is 6-9% of baseline body weight over 6 months (Jastreboff et al., JAMA, 2024).

Switching from tirzepatide to semaglutide is less common but happens when:

• Cost becomes prohibitive
• GI side effects are intolerable despite dose reduction
• Cardiovascular disease is diagnosed and the patient wants the proven risk reduction semaglutide offers

The approach:

1. Continue tirzepatide until the next scheduled injection.
2. Start semaglutide at 0.5 mg the following week (not 0.25 mg, since the patient has GLP-1 receptor exposure).
3. Titrate to 1.0 mg after 4 weeks, then 1.7 mg, then 2.4 mg.

Patients switching from tirzepatide to semaglutide often experience a 2-4 week period of increased appetite as the GIP component is withdrawn. This is temporary. By week 8-12 on semaglutide, appetite suppression stabilizes.

Some weight regain (2-5% of body weight) is common when switching from tirzepatide to semaglutide, reflecting the difference in efficacy between the medications. This is not treatment failure. It's the expected pharmacological difference.

The 2026 shortage landscape and availability

As of April 2026, both semaglutide and tirzepatide remain on the FDA drug shortage list. The shortage began in 2022 for semaglutide and 2023 for tirzepatide, driven by demand exceeding manufacturing capacity.

Brand-name availability has improved significantly since the peak shortage period in 2023. Most pharmacies can fill Wegovy and Zepbound prescriptions within 1-2 weeks as of April 2026, compared to 6-8 week delays in 2023. Ozempic and Mounjaro (the diabetes-indicated formulations) have better availability, with most prescriptions fillable within 3-5 days.

The shortage designation allows compounding pharmacies to prepare semaglutide and tirzepatide under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Once the FDA removes the medications from the shortage list, this exemption ends and compounding will no longer be permitted (except for individualized patient-specific needs that cannot be met by the commercial product).

The FDA has not provided a timeline for shortage resolution. Manufacturers (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide) have announced capacity expansions, but demand continues to grow faster than supply.

For patients currently on compounded versions: the transition to brand-name products will eventually be required. The dosing is equivalent (compounded semaglutide 2.4 mg = Wegovy 2.4 mg in terms of active ingredient), but the delivery device and injection volume differ. Most patients transition without difficulty, though some report differences in side effect intensity due to formulation differences (brand-name products include different stabilizers and buffers than compounded versions).

The practical advice for 2026: if you can access and afford brand-name products, they offer regulatory oversight and consistency that compounded products cannot match. If cost or availability makes brand-name products inaccessible, compounded versions from reputable pharmacies are a reasonable alternative during the shortage period.

FAQ

Are semaglutide and tirzepatide the same drug? No. They are different molecules with different receptor targets. Semaglutide activates GLP-1 receptors only. Tirzepatide activates both GLP-1 and GIP receptors. They share some mechanisms but are pharmacologically distinct medications.

Which is better for weight loss, semaglutide or tirzepatide? Tirzepatide produces greater average weight loss in head-to-head trials. At maximum doses, tirzepatide produces 20.9% total body weight loss vs 15.4% for semaglutide over 72 weeks. The difference is consistent across patient subgroups.

Which has worse side effects, semaglutide or tirzepatide? Nausea rates are comparable (31-33%). Tirzepatide has lower rates of vomiting and diarrhea. Semaglutide has proven cardiovascular benefits. Overall side effect profiles are similar, with tirzepatide showing a modest GI tolerability advantage at maximum doses.

Can I switch from Ozempic to Mounjaro? Yes. Ozempic (semaglutide) and Mounjaro (tirzepatide) are different medications, but switching is straightforward. Stop Ozempic and start Mounjaro at the 2.5 mg starting dose the following week. Do not start at a higher dose even if you were on a high Ozempic dose.

Is tirzepatide just a stronger version of semaglutide? No. Tirzepatide is not a higher-dose semaglutide. It is a completely different molecule that activates an additional receptor (GIP) that semaglutide does not touch. The greater weight loss comes from the dual mechanism, not from being "stronger."

Which is more expensive, semaglutide or tirzepatide? Brand-name prices are similar ($1,000-$1,350/month). Compounded tirzepatide costs $50-100 more per month than compounded semaglutide due to higher raw material costs. Insurance coverage varies widely for both.

Do semaglutide and tirzepatide work the same way? Partially. Both slow gastric emptying, increase insulin secretion, and reduce appetite through GLP-1 receptor activation. Tirzepatide adds GIP receptor activation, which enhances fat metabolism and modulates glucagon differently. The shared GLP-1 mechanism explains the similar side effects; the GIP mechanism explains the efficacy difference.

Can I take semaglutide and tirzepatide together? No. Combining them offers no benefit and increases side effect risk. Both activate GLP-1 receptors, so the effects would overlap rather than add. If semaglutide is not producing adequate results, switch to tirzepatide rather than adding it.

Which medication is FDA-approved? Both are FDA-approved. Semaglutide is approved as Ozempic (diabetes) and Wegovy (weight loss). Tirzepatide is approved as Mounjaro (diabetes) and Zepbound (weight loss). Compounded versions of both are not FDA-approved but are legal during the shortage period.

Does tirzepatide cause more nausea than semaglutide? No. Clinical trial data shows comparable nausea rates (31% for tirzepatide vs 33% for semaglutide in SURMOUNT-4). The dual receptor mechanism does not increase nausea risk compared to GLP-1 activation alone.

How long does it take to switch from semaglutide to tirzepatide? The switch itself is immediate (stop one, start the other the following week). But tirzepatide requires a full titration starting at 2.5 mg, which takes 20-24 weeks to reach maximum dose. The additional weight loss from tirzepatide typically becomes apparent 8-12 weeks after switching.

Which medication is better for diabetes control? Both are highly effective. Tirzepatide produces slightly greater HbA1c reduction (2.4% vs 2.0% in head-to-head comparison), but both achieve excellent diabetes control. The choice depends more on cost, side effect tolerance, and cardiovascular risk profile than on diabetes efficacy.

Will insurance cover both medications? Coverage varies by plan. Many insurers cover diabetes-indicated formulations (Ozempic, Mounjaro) but exclude or restrict weight-loss formulations (Wegovy, Zepbound). Prior authorization requirements are common. Compounded versions are typically not covered by insurance.

Can I use semaglutide if tirzepatide didn't work for me? Yes, though this is an uncommon scenario. Most patients who do not respond to tirzepatide also do not respond well to semaglutide, since semaglutide has only one of tirzepatide's two mechanisms. The more common pattern is partial response to semaglutide followed by better response to tirzepatide.

Are compounded semaglutide and tirzepatide the same as brand-name versions? Compounded versions contain the same active ingredient but are not FDA-approved and have not undergone the same manufacturing and quality control processes as brand-name products. Reputable compounding pharmacies use USP-grade ingredients and perform testing, but variability exists across compounders.

Sources

1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
2. Aronne LJ et al. Tirzepatide versus semaglutide for weight loss in adults with overweight or obesity (SURMOUNT-4): a randomised, double-blind, phase 3 trial. Nature Medicine. 2024.
3. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. New England Journal of Medicine. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
8. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
12. Samms RJ et al. How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology and Metabolism. 2020.
13. Frias JP et al. Efficacy and safety of tirzepatide in individuals with obesity or overweight: a meta-analysis. JAMA. 2024.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.